Chelation Therapy for Off-Label Uses
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs coverage of chelation therapy for off-label indications (Alzheimer disease, atherosclerosis/cardiovascular disease, autism spectrum disorder, diabetes, multiple sclerosis, arthritis) and notes FDA-approved indications and guidance; defines these off-label uses as experimental/investigational and not covered. Applies to professional and institutional settings for BCBSKS members.
Policy states off-label applications (Alzheimer disease, atherosclerosis, autism, diabetes, multiple sclerosis, arthritis) are experimental/investigational.
Policy title changed to 'Chelation Therapy for Off-Label Uses' and policy language updated to restate FDA-approved indications in Policy Guidelines and identify off-label uses as experimental/investigational.
Policy guideline updated to change phrasing for iron overload indication to 'or' (transfusional hemosiderosis or NTDT).
Coding section updated over time (CPT correction: replaced 96375 with 96374) and removal of ICD diagnosis box; appendix changes and removal.
Coverage Summary
Overview: This policy governs coverage of chelation therapy for off-label indications (including Alzheimer disease, atherosclerosis/cardiovascular disease, autism spectrum disorder, diabetes, multiple sclerosis, and arthritis) and designates these off-label uses as experimental/investigational and not covered. FDA-approved indications for chelation therapy (listed in Policy Guidelines) are acknowledged as standard of care but coverage for those FDA-approved uses is subject to the member's contract benefits and applicable state/federal mandates. Effective date: 2016-08-19. Last review: 2025-03-27.
Medical-Necessity Criteria
Coverage Determination
Off-label applications of chelation therapy are considered experimental / investigational (not covered) when used for the following indications:
ALL of the following
Any of the following off-label indications
- Alzheimer's disease
- Atherosclerosis (e.g., coronary artery disease, secondary prevention in individuals with myocardial infarction, or peripheral vascular disease)
- Autism
- Diabetes
- Multiple sclerosis
- Arthritis (includes rheumatoid arthritis)
FDA-approved / Standard Indications (policy guidelines)
Chelation therapy is considered standard of care (coverage subject to member contract benefits) for specific FDA-approved indications:
ALL of the following
FDA-approved indications
- Extreme conditions of metal toxicity
- Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to non-transfusion-dependent thalassemia (NTDT)
- Wilson disease (hepatolenticular degeneration)
- Lead poisoning
- Control of ventricular arrhythmias or heart block associated with digitalis toxicity
- Emergency treatment of hypercalcemia
- Coverage condition: Coverage for FDA-approved indications is subject to the member's contract benefits in effect at time of service
Policy Guidelines / Indications Considered Standard of Care
Chelation therapy is considered standard of care for specific FDA-approved indications (Policy Guidelines). Notes describe alternative therapies and EDTA approval removal.
Policy Guidelines - Standard of Care Indications
- Extreme conditions of metal toxicity (FDA-approved)
- Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to non-transfusion-dependent thalassemia (NTDT)
- Wilson disease (hepatolenticular degeneration)
- Lead poisoning
- Control of ventricular arrhythmias or heart block associated with digitalis toxicity (note: most patients treated with other modalities such as Fab monoclonal antibodies)
- Emergency treatment of hypercalcemia (note: FDA removed approval for NaEDTA; other chelators recommended)
Off-Label Applications / Experimental / Investigational
Off-label applications of chelation therapy are considered experimental/investigational and not supported by randomized controlled trial evidence or have trial-level limitations:
Evidence summary
- Off-label uses (including but not limited to treatment of atherosclerotic cardiovascular disease, peripheral artery disease, multiple sclerosis, arthritis, Parkinson disease, Alzheimer disease, autism spectrum disorder) are experimental/investigational
- Randomized trials for Alzheimer disease (PBT1/clioquinol, PBT2) found no significant cognitive benefit; recent 2025 deferiprone RCT showed accelerated cognitive decline with deferiprone versus placebo
- RCT evidence for cardiovascular disease (eg, TACT) had important limitations (high dropout, composite endpoint, subgroup findings) and TACT2 (2024) failed to replicate TACT findings
- No randomized controlled trials or controlled trials identified to support safety and efficacy for multiple sclerosis or arthritis
- Small single-blind RCT for diabetic nephropathy (Chen 2012) showed slower eGFR decline but is insufficient; larger RCTs reporting clinical outcomes are needed
Coding (informational)
| No codes listed |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
| 96366 | Intravenous infusion; each additional hour |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug |
| M0300 | IV chelation therapy (chemical endarterectomy) |
| S9355 | Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem |
Provider Actions & Billing Impact
Verify member benefits
Providers must verify a member's benefits and consider state/federal mandates and contract language which take precedence over this medical policy.
Prior authorization and coverage determination
Coverage of chelation for FDA-approved indications should be determined per member contract benefits; off-label uses are considered experimental/investigational and will not be covered.
Adhere to Policy Indications
Providers must ensure chelation therapy is performed only for medically necessary, FDA-approved indications listed in policy guidelines to be considered standard of care; off-label uses are considered experimental/investigational and are not supported by the policy.
Use Listed Procedure/Drug Codes for Chelation Services
When chelation therapy is performed per the policy, report the applicable infusion, injection, or drug J/HCPCS codes provided in the coding section; inclusion of codes is informational and does not guarantee coverage — verify member contract benefits.
Background
Background: Chelation therapy involves intravenous or oral administration of chelating agents that bind metal ions to facilitate excretion and is an established treatment for certain heavy metal toxicities and transfusional hemosiderosis. A subclass of agents, metal protein attenuating compounds (MPACs), has been investigated for Alzheimer disease because they modulate cerebral metal interactions rather than producing systemic metal removal; however, no MPACs have received FDA approval for Alzheimer disease. Several iron chelators are FDA-approved for iron overload: deferoxamine (approved for acute iron intoxication and chronic iron overload due to transfusion-dependent anemia), deferasirox (approved for chronic iron overload due to transfusions and, under expanded/accelerated indications, some non–transfusion-dependent thalassemia patients; carries boxed warnings for serious renal, hepatic, and gastrointestinal toxicity and requires monitoring), and deferiprone (approved for transfusional overload due to thalassemia when other chelation is inadequate; carries a boxed warning for agranulocytosis requiring absolute neutrophil count monitoring). The FDA has also withdrawn or modified approvals for some chelators (for example, disodium-EDTA approval was withdrawn for certain uses because of safety concerns).
Evidence Summary
Evidence overview: The policy summarizes randomized controlled trials and systematic reviews assessing chelation therapy for off-label indications. Systematic reviews and meta-analyses of EDTA chelation for cardiovascular disease found insufficient evidence to support efficacy, and the largest RCT (TACT, n=1708) reported a small composite endpoint benefit but had important limitations; a subsequent replication trial (TACT2) failed to confirm the original TACT findings. For Alzheimer disease, small RCTs of MPACs (PBT1/clioquinol and PBT2) did not show cognitive benefit, and a 2025 phase 2 RCT of the iron chelator deferiprone showed accelerated cognitive decline versus placebo. For diabetic nephropathy, a single small single-blind RCT reported slower eGFR decline but is insufficient to establish efficacy. Overall, available RCTs and systematic reviews do not provide adequate, consistent evidence of net benefit for the off-label uses summarized below.
Medicare Determinations
| Number | Name | Type | Effective Date |
|---|---|---|---|
| 20.21 | CHELATION THERAPY for Treatment of Atherosclerosis | NCD | |
| 20.22 | Ethylenediamine-Tetra-Acetic (EDTA) CHELATION THERAPY for Treatment of Atherosclerosis | NCD |
Revision History
Policy Guidelines list FDA-approved indications separately; no explicit material change indicated in this part. Policy states off-label applications (Alzheimer disease, atherosclerosis, autism, diabetes, multiple sclerosis, arthritis) are experimental/investigational.
Policy title changed to 'Chelation Therapy for Off-Label Uses' and policy language updated to restate FDA-approved indications in Policy Guidelines and identify off-label uses as experimental/investigational.
Multiple historical coding and appendix revisions listed; coding section updated over time (CPT correction: replaced 96375 with 96374) and removal/addition of appendix items.
Updated policy guideline 1b wording to change 'and' to 'or' for the iron overload indication (transfusional hemosiderosis or NTDT).
Multiple historical coding and appendix revisions recorded through 2025-03-27, including removal of ICD diagnosis box and ongoing updates to description, rationale, and references.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.